Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lexis Pharmaceuticals

Executive Summary

Ad campaign for Lexis Health Plan began Nov. 6 on TV and radio in Kansas City. The company, which launched the first TV ads for oral contraceptives last June, is offering $ 50 toward the cost of a medical examination, or a $ 10 rebate for women who have purchased a six-month supply of Lexis' generic oral contraceptive N.E.E. 1/35 (norethindrone and ethinyl estradiol). Like the earlier ads, the TV spots appearing on CBS affiliate KCTV, ABC affiliate KMBC-TV, independent station KZKC-TV and radio stations KXXR-AM and KCMD focus on the 50% difference in cost between N.E.E. 1/35 and the brandname products, Ortho's Ortho-Novum 1/35 and Syntex' Norinyl 1/35.

You may also be interested in...



Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States

Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS016537

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel